alcian-blue has been researched along with 1-9-dimethylmethylene-blue* in 2 studies
2 other study(ies) available for alcian-blue and 1-9-dimethylmethylene-blue
Article | Year |
---|---|
Mucopolysaccharidoses screening: dimethylmethylene blue versus alcian blue.
The dimethylmethylene blue (DMB)-based screening procedure for mucopolysaccharidosis and the alcian blue (AB)-based procedure both measure glycosaminoglycan (GAG) content directly in urine. We compared the two procedures. Absorbance per microgram of GAG for DMB was 25 times that obtained with AB, resulting in a requirement for 10 times smaller sample volumes for the former. Recoveries of added heparan sulphate for the AB assay in the absence and presence of added protein (2.5 g/L) were comparable (78-95% and 75-111%), as was the case with the DMB assay. Here, recoveries were generally better (94-103% and 96-100%). The coefficient of correlation (CC) between the two methods measured on 86 reference urine samples was 0.861. For mucopolysaccharidosis urines the CC was higher (0.928). Age-dependent reference values were comparable. Performance of the assays was compared by measurement of GAG content in 24 mucopolysaccharidosis urines. Standard deviation scores (measured value minus mean of reference values divided by standard deviation in reference values) and probabilities for classification in the patient group were calculated and compared. Especially for urines from patients with less distinctly increased GAG content (Sanfilippo, Scheie), scores and probabilities were higher with the DMB assay. Topics: Adolescent; Adult; Alcian Blue; Child; Child, Preschool; Glycosaminoglycans; Humans; Infant; Methylene Blue; Middle Aged; Mucopolysaccharidoses; Sensitivity and Specificity | 1994 |
Urinary glycosaminoglycan excretion in rheumatic diseases.
We used Alcian Blue (AB) and dimethylmethylene blue (DMB) methods to measure glycosaminoglycan (GAG) excretion in the first morning urine specimens of patients with osteoarthritis (OA), ankylosing spondylitis (AS), and rheumatoid arthritis (RA) in different stages of disease. By the AB method, urinary GAG excretion in patients with RA was not different from healthy control subjects. However, the DMB method showed significant differences (in milligrams of GAG per gram of creatinine) for OA (median 25.4, range 14.3-44.0, P less than 0.01, n = 23) and RA patients (median 33.0; range 10.0-147.6; P less than 0.001, n = 63) in comparison with unaffected individuals (median 20.2; range 8.9-41.4, n = 38). We noted a significant difference in urinary GAG excretion between RA and OA patients (P less than 0.01) and between RA and AS (P less than 0.01) patients. The DMB method was further investigated by clinical decision analysis. The DMB method is simple and rapid and may be useful in diagnosing RA by distinguishing between RA and OA or AS. Topics: Adolescent; Adult; Aged; Alcian Blue; Arthritis, Rheumatoid; Glycosaminoglycans; Humans; Methylene Blue; Middle Aged; Osteoarthritis; Rheumatic Diseases; Spectrophotometry; Spondylitis, Ankylosing | 1992 |